Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066685 · ClinicalTrials.gov registry record
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 18,457
- Enrollment target
NCT05066685: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05066685 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 18,457 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05066685 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 18,457 participants
- Enrollment target
Study Summary
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
Primary Outcome
The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance.
Interventions
- OTHER All participants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,457 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2020-09-25 |
What the finished NCT05066685 record still lists
NCT05066685 is an observational study that tracks outcomes without assigning an intervention. Its 18,457 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which All participants is the first listed.
NCT05066685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05066685 about?
NCT05066685 is a clinical study titled "Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program". The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
What is the current status of trial NCT05066685?
This trial is currently completed. The enrollment target is 18,457 participants. The study started on 2020-08-11. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT05066685?
The interventions under investigation include: All participants (OTHER).
Who is sponsoring clinical trial NCT05066685?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI